ストックスクリーナーアプリを入手
3.02
3.07%
0.09
アフターアワーズ：
3.00
-0.02
-0.66%
前日終値:
$2.93
開ける：
$3
24時間の取引高:
4.56M
Relative Volume:
3.52
時価総額：
$489.08M
収益：
-
当期純損益:
$-274.18M
株価収益率:
-1.1915
EPS:
-2.5346
ネットキャッシュフロー:
$-198.33M
1週間 パフォーマンス:
+14.83%
1か月 パフォーマンス:
+65.93%
6か月 パフォーマンス:
+287.28%
1年 パフォーマンス:
-73.62%
1日の値動き範囲:
$2.82
$3.25
1週間の範囲:
$2.40
$3.25
52週間の値動き範囲:
$0.611
$14.09
Neumora Therapeutics Inc Stock (NMRA) Company Profile
名前
Neumora Therapeutics Inc
セクター
電話
(857) 760-0900
住所
260 ARSENAL PLACE, SUITE 1, WATERTOWN
NMRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
3.02 | 474.50M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | -52.09M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-09-16 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-04-02 | ダウングレード | BofA Securities | Buy → Underperform |
| 2025-03-10 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-07 | ダウングレード | Stifel | Buy → Hold |
| 2025-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-22 | 開始されました | Needham | Buy |
| 2024-07-08 | 開始されました | Mizuho | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Hold |
| 2023-10-10 | 開始されました | BofA Securities | Buy |
| 2023-10-10 | 開始されました | Guggenheim | Buy |
| 2023-10-10 | 開始されました | JP Morgan | Overweight |
| 2023-10-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-10-10 | 開始されました | Stifel | Buy |
| 2023-10-10 | 開始されました | William Blair | Outperform |
すべてを表示
Neumora Therapeutics Inc (NMRA) 最新ニュース
What risks investors should watch in Neumora Therapeutics Inc. stockQuarterly Performance Summary & Verified Chart Pattern Trade Signals - newser.com
Will Neumora Therapeutics’ (NMRA) Novel Drug Pipeline Define Its Competitive Edge in Biotech? - simplywall.st
What momentum shifts mean for Neumora Therapeutics Inc.July 2025 WrapUp & Expert Curated Trade Setup Alerts - newser.com
Is Neumora Therapeutics Inc. stock entering bullish territory2025 Market Sentiment & Reliable Price Action Trade Plans - newser.com
Regression analysis insights on Neumora Therapeutics Inc. performance2025 Year in Review & Daily Profit Maximizing Tips - newser.com
Heatmap analysis for Neumora Therapeutics Inc. and competitors2025 Dividend Review & Free High Accuracy Swing Entry Alerts - newser.com
Why Neumora Therapeutics Inc. stock is a must watch in 2025July 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
Neumora Therapeutics Inc. stock outlook for YEARJuly 2025 Review & Free Safe Capital Growth Stock Tips - newser.com
Published on: 2025-10-31 04:44:03 - newser.com
Published on: 2025-10-31 03:53:08 - newser.com
How moving averages guide Neumora Therapeutics Inc. trading2025 Sector Review & Low Risk High Win Rate Picks - newser.com
Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity - Yahoo Finance
Can a trend reversal in Neumora Therapeutics Inc. lead to recoveryExit Point & AI Driven Price Predictions - newser.com
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating - Insider Monkey
Arch Venture Partners Xii, Llc Acquires 1,915,700 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Director Kristina Burow Acquires 1,915,700 Shares - MarketBeat
Is Neumora Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 News Drivers & AI Powered Market Entry Ideas - newser.com
Neumora Therapeutics Stock (NMRA) Opinions on Obesity Drug Data Release - Quiver Quantitative
Guggenheim upgrades Neumora Therapeutics, Inc. (NMRA) to a Buy - The Globe and Mail
Neumora to initiate phase 1 study of oral obesity pill - MSN
Published on: 2025-10-30 01:21:45 - newser.com
Major Stakeholders Make Bold Moves in Neumora Therapeutics! - TipRanks
Neumora Therapeutics (NASDAQ:NMRA) Price Target Raised to $8.00 - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Is Neumora Therapeutics Inc. stock a top pick in earnings season2025 Buyback Activity & Safe Entry Zone Tips - Fundação Cultural do Pará
14 Stocks Under $5 with Highest Upside Potential - Insider Monkey
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $5 to $18 - 富途牛牛
Needham Maintains Neumora Therapeutics (NMRA) Buy Recommendation - Nasdaq
Why hedge funds are buying Neumora Therapeutics Inc. stock2025 Market Trends & Weekly Top Gainers Alerts - Fundação Cultural do Pará
Real time social sentiment graph for Neumora Therapeutics Inc.2025 Top Gainers & Verified Entry Point Signals - newser.com
Published on: 2025-10-30 01:45:00 - newser.com
Will Neumora Therapeutics Inc. stock reach Wall Street targetsEarnings Recap Summary & Weekly Hot Stock Watchlists - Fundação Cultural do Pará
Neumora initiates phase 1 study of second M4 PAM compound By Investing.com - Investing.com Philippines
How Neumora Therapeutics Inc. stock valuations compare to rivalsPortfolio Return Report & Free Safe Entry Trade Signal Reports - Fundação Cultural do Pará
Neumora’s obesity drug shows up to 26% weight loss in preclinical studies - Investing.com Canada
Neumora Therapeutics’ Phase 3 Study on NMRA-335140: A Potential Breakthrough for Major Depressive Disorder - TipRanks
Neumora Therapeutics’ NMRA-323511 Study: A Potential Breakthrough in Alzheimer’s Treatment - TipRanks
Neumora initiates phase 1 study of second M4 PAM compound - Investing.com
How Neumora Therapeutics Inc. stock performs after earnings2025 Key Highlights & Free Community Consensus Stock Picks - Fundação Cultural do Pará
Is Neumora Therapeutics Inc. stock positioned well for digital economyJuly 2025 Movers & Low Risk High Reward Trade Ideas - Fundação Cultural do Pará
Neumora Therapeutics Inc (NMRA) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):